Genkyotex Plans 'Solo' Pivotal Trials After Lead Product Hits Phase II PBC Targets
The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.
You may also be interested in...
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
The latest drug development news and highlights from our US FDA Performance Tracker.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.